Last reviewed · How we verify
KLH, peptides plus Montanide
At a glance
| Generic name | KLH, peptides plus Montanide |
|---|---|
| Sponsor | Dr. Nina Bhardwaj |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (PHASE2)
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (PHASE2)
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (PHASE1)
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (PHASE1)
- Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence (PHASE2)
- SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (PHASE2)
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLH, peptides plus Montanide CI brief — competitive landscape report
- KLH, peptides plus Montanide updates RSS · CI watch RSS
- Dr. Nina Bhardwaj portfolio CI